Beta Bionics, Inc. Chief Medical Officer Steven Jon Russell filed a Form 4 on September 3, 2026, reporting the sale of common stock on September 2, 2026, to cover tax withholding obligations tied to the vesting of restricted stock units.

Key Highlights

  • Shares sold: 4,221 shares of Beta Bionics common stock were disposed of on September 2, 2026.
  • Weighted average price: The transaction was executed at a weighted average sale price of $19.1131 per share.
  • Price range: Individual sale prices ranged between $18.89 and $19.545 per share.
  • Purpose of sale: According to the filing, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
  • Remaining ownership: Following the transaction, Russell directly holds 169,628 shares of common stock.
  • Reporting person role: Russell is identified in the filing as Chief Medical Officer of Beta Bionics, Inc. (NASDAQ:BBNX).

Beta Bionics CMO Reports RSU Tax-Withholding Sale of Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc. (NASDAQ:BBNX), disposed of 4,221 shares of common stock on September 2, 2026. The filing indicates the transaction code was "S," reflecting a sale, and that the shares were sold directly by the reporting person.

The filing states that the shares were sold specifically "to cover tax withholding obligations associated with the vesting of restricted stock units." The weighted average sale price reported was $19.1131 per share, with individual transactions occurring across a price range of $18.89 to $19.545. The filing notes that full information on the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder.

Following the reported transaction, Russell's direct beneficial ownership stands at 169,628 shares of Beta Bionics common stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The filing was signed by Stephen Feider as attorney-in-fact on September 3, 2026.

What Was Disclosed

The filing discloses a single sale of 4,221 shares of Beta Bionics common stock by the company's Chief Medical Officer on September 2, 2026, at a weighted average price of $19.1131, conducted to satisfy tax withholding obligations from RSU vesting, leaving the officer with 169,628 shares.